Completed PHASE3 INTERVENTIONAL NCT00150449

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders

Sponsor: Pfizer

Interventions Pregabalin

Updated 6 times since 2017 Last updated: Jul 13, 2006 Started: Jan 31, 2001 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00150449, this PHASE3 trial focuses on Anxiety Neuroses and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2001, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A-1040 Wien, Austria , BV Losser, Netherlands , Bad-Deurrheim, Germany , Bangor, United Kingdom , Barcelona, Spain , Bassano Del Grappa (Vicenza), Italy , Bellville, South Africa , Bexhill-on-Sea, United Kingdom , Bialystok, Poland , Birmingham, United Kingdom and 109 more locations